Infection therapy: the problem of drug resistance – and possible solutions. Issue 5 (24th July 2017)

• Record Type: Journal Article
• Authors: Brüssow, Harald
• Other Names: Morgenroth Eberhard guestEditor.; Flemming Hans‐Curt guestEditor.; Azeredo Joana guestEditor.; Melo Luis F. guestEditor.; Espinosa Manuel guestEditor.; Whiteley Marvin guestEditor.; Briandet Romain guestEditor.
• Is Part Of: Microbial biotechnology. Volume 10:Issue 5(2017:Sep.)
• Page Start: 1041
• Page End: 1046
• Publication Date: 2017-07-24
• Subjects: Microbial biotechnology -- Periodicals; Biotechnology; Microbiology; 660.62
• DOI: 10.1111/1751-7915.12777
• Languages: English
• ISSNs: 1751-7915

Abstract

Summary: The rising antibiotic resistance in major bacterial pathogens together with the breakdown of the antibiotic discovery platform creates a critical situation for infection therapy. Recent developments reviving new antibiotic discovery from defining chemical rules for membrane‐passing compounds to isolation chips for soil bacteria and exploring the human microbiome for antibiotic‐producing bacteria are discussed. The potential of bacteriocins, tailocins, phage lysins, phages, probiotics and commensal blends as alternatives to antibiotics is evaluated. Abstract : The rising antibiotic resistance in major bacterial pathogens together with the breakdown of the antibiotic discovery platform creates a critical situation for infection therapy. Recent developments reviving new antibiotic discovery from defining chemical rules for membrane‐passing compounds to isolation chips for soil bacteria and exploring the human microbiome for antibiotic‐producing bacteria are discussed. The potential of bacteriocins, tailocins, phage lysins, phages, probiotics and commensal blends as alternatives to antibiotics are evaluated. Chemical formula are from Wikipedia (public domain) and microscopies from publications of the author (Microbe 2:341 (2007) and Curr Opin Microbiol 6:417 (2003)).